TJHA
TEVA icon

Thomas J. Herzfeld Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-168
Closed -$2K – 369
2021
Q1 		$2K Buy
168
+2
+1% +$23 ﹤0.01% 348
2020
Q4 		$2K Hold
166
– – ﹤0.01% 293
2020
Q3 		$1K Buy
+166
New +$1.76K ﹤0.01% 254
2017
Q1 		– Sell
-430
Closed -$16K – 310
2016
Q4 		$16K Sell
430
-515
-54% -$20.6K 0.01% 288
2016
Q3 		$43K Sell
945
-149
-14% -$7.77K 0.02% 193
2016
Q2 		$55K Buy
1,094
+282
+35% +$15K 0.03% 189
2016
Q1 		$43K Sell
812
-234
-22% -$13.7K 0.02% 214
2015
Q4 		$69K Buy
1,046
+147
+16% +$9.08K 0.03% 188
2015
Q3 		$51K Sell
899
-299
-25% -$19.4K 0.02% 191
2015
Q2 		$71K Buy
1,198
+615
+105% +$37.9K 0.03% 169
2015
Q1 		$36K Buy
583
+467
+403% +$27.2K 0.02% 199
2014
Q4 		$7K Buy
+116
New +$6.46K ﹤0.01% 274

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Thomas J. Herzfeld Advisors's TEVA Position: Q2 2021 in Review

Thomas J. Herzfeld Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2021, closing a stake of 168 shares — an estimated $2K sold.

Thomas J. Herzfeld Advisors first reported a position in TEVA in Q4 2014 and held it in 12 quarters. The position peaked at $71K in Q2 2015. 440 funds tracked by Wall St. Rank hold TEVA as of Q2 2021.

  • Thomas J. Herzfeld Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Thomas J. Herzfeld Advisors sold 168 Teva Pharmaceuticals shares in Q2 2021, an estimated $2K.
  • Thomas J. Herzfeld Advisors first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 12 quarters.
  • Thomas J. Herzfeld Advisors's Teva Pharmaceuticals position peaked at $71K in Q2 2015.
  • 440 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2021.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.